Bristol-Myers Squibb (NY:BMY)

61.15 +0.32 (+0.53%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

93 94 Next >

3 Dirt Cheap Dividend Stocks Worth Buying in October ↗

October 04, 2026

There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns ↗

October 03, 2026

Via Chartmill

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗

October 03, 2026

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 01, 2026

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.

Via The Motley Fool

Topics Economy

Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question ↗

September 10, 2026

Via Chartmill

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale ↗

October 01, 2026

Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.

Via The Motley Fool

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

October 01, 2026

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

September 30, 2026

From Bristol Myers Squibb

Via Business Wire

Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks

September 29, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 29, 2026

Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.

Via The Motley Fool

Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗

September 29, 2026

Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.

Via The Motley Fool

Topics Intellectual Property

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation ↗

September 29, 2026

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

Via The Motley Fool

Topics Intellectual Property

1 Cash-Producing Stock to Keep an Eye On and 2 Facing Challenges

September 29, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Via StockStory

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 27, 2026

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.

Via The Motley Fool

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗

September 27, 2026

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Via The Motley Fool

Topics Bonds Economy

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

September 25, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Via The Motley Fool

Topics Intellectual Property Regulatory Compliance

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗

September 24, 2026

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

Via The Motley Fool

Topics Intellectual Property

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗

September 20, 2026

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

September 18, 2026

From Bristol Myers Squibb

Via Business Wire

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

September 17, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

September 17, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend

September 16, 2026

From Bristol Myers Squibb

Via Business Wire

3 Healthcare Stocks That Fall Short

September 14, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? ↗

September 13, 2026

As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.

Via The Motley Fool

Topics Intellectual Property

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

September 10, 2026

Via Investor Brand Network

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

September 10, 2026

Via Investor Brand Network

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

From BioMedWire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.